Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants

• Published in: Orphanet journal of rare diseases Vol. 18; no. 1; p. 231
• Main Authors: Chan, Mei-Yan, Jalil, Julaina Abdul, Yakob, Yusnita, Wahab, Siti Aishah Abdul, Ali, Ernie Zuraida, Khalid, Mohd Khairul Nizam Mohd, Leong, Huey-Yin, Chew, Hui-Bein, Sivabalakrishnan, Jeya Bawani, Ngu, Lock-Hock
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 04.08.2023; BioMed Central; BMC
• Subjects: Acid alpha-glucosidase; Age; Amylases; Analysis; Cardiomyopathy; Care and treatment; Clinical outcomes; Crystal structure; Diagnosis; DNA sequencing; Enzyme replacement therapy; Enzymes; Exons; Failure to thrive; GAA; Gene deletion; Gene frequency; Genetic aspects; Genotypes; Glycogen; Glycogenosis; Health aspects; Infantile-onset Pompe disease; Lysosomal storage disease; Medical research; Medicine, Experimental; Mutation; Nucleotide sequencing; Patients; Phenotype; Phenotypes; Polymorphism; Proteins; Rare diseases; Statistical analysis; Survival; α-Glucosidase; Malaysia; China; Acid alpha-glucosidase; Infantile-onset Pompe disease; Lysosomal storage disease; Enzyme replacement therapy; GAA
• ISSN: 1750-1172; 1750-1172
• DOI: 10.1186/s13023-023-02848-6

Pompe disease is a rare glycogen storage disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA), leading to glycogen deposition in multiple tissues. Infantile-onset Pompe disease (IOPD) patients present within the first year of life with profound hypotonia and hypertrophic cardiomyopathy. Treatment with enzyme replacement therapy (ERT) has significantly improved survival for this otherwise lethal disorder. This study aims to describe the clinical and molecular spectrum of Malaysian IOPD patients, and to analyze their long term treatment outcomes. Seventeen patients diagnosed with IOPD between 2000 and 2020 were included in this retrospective cohort study. Clinical and biochemical data were collated and analyzed using descriptive statistics. GAA enzyme levels were performed on dried blood spots. Molecular analysis of the GAA gene was performed by polymerase chain reaction and Sanger sequencing. Structural modelling was used to predict the effect of the novel mutations on enzyme structure. Our cohort had a median age of presentation of 3 months and median age of diagnosis of 6 months. Presenting features were hypertrophic cardiomyopathy (100%), respiratory insufficiency (94%), hypotonia (88%), failure to thrive (82%), feeding difficulties (76%), and hepatomegaly (76%). Fourteen different mutations in the GAA gene were identified, with three novel mutations, c.1552-14_1552-1del, exons 2-3 deletion and exons 6-10 deletion. The most common mutation identified was c.1935C > A p.(D645E), with an allele frequency of 33%. Sixteen patients received ERT at the median age of 7 months. Overall survival was 29%. Mean age of death was 17.5 months. Our longest surviving patient has atypical IOPD and is currently 20 years old. This is the first study to analyze the genotype and phenotype of Malaysian IOPD patients, and has identified the c.1935C > A p.(D645E) as the most common mutation. The three novel mutations reported in this study expands the mutation spectrum for IOPD. Our low survival rate underscores the importance of early diagnosis and treatment in achieving better treatment outcomes.